Literature DB >> 32246145

Genetic Study in a Large Cohort Supported Different Pathogenesis of Graves' Disease and Hashimoto's Hypothyroidism.

Qian-Yue Zhang1, Wei Liu1,2, Lu Li1, Wen-Hua Du3, Chun-Lin Zuo4, Xiao-Ping Ye1, Zheng Zhou1, Fei-Fei Yuan1, Yu-Ru Ma1, Feng Sun1, Sha-Sha Yu1, Hui-Jun Xie1, Chang-Run Zhang1, Ying-Xia Ying1, Guo-Yue Yuan5, Guan-Qi Gao3, Jun Liang6, Shuang-Xia Zhao1, Huai-Dong Song1,2.   

Abstract

CONTEXT: Hashimoto's thyroiditis (HT) and Graves' disease (GD) are the 2 main autoimmune thyroid diseases that have both similarities and differences. Determining the genetic basis that distinguishes HT from GD is key for a better understanding of the differences between these closely related diseases. OBJECTS: To identify the susceptibility genes for HT in the Chinese cohort and compare susceptibility genes between GD and HT.
DESIGN: In the current study, 18 SNPs from 18 established GD risk loci were selected and then genotyped in 2682 patients with HT, 4980 patients with GD, and 3892 controls. The association analysis between HT and controls and heterogeneity analysis between HT and GD were performed on SPSS, with the logistic regression analysis adjusted for sex and age.
RESULTS: We identified 11 susceptibility loci for HT in the Chinese Han population, with 4 loci, including the rs1265883 in SLAMF6 locus, rs1024161 in CTLA4, rs1521 in HLA-B, and rs5912838 in GPR174/ ITM2A at X chromosome, reaching genome-wide significance of 5 × 10-8. Five loci were reported to be associated with HT for the first time. We also identified 6 susceptibility loci with heterogeneity between GD and HT. Out of them, 4 loci were associated with GD but not with HT, including HLA-DPB1, CD40, TSHR, and TG; the association of HLA-B with GD was stronger than that with HT, but the association of SLAMF6 was reversed.
CONCLUSION: Our findings suggested that the pathogenesis of HT and GD was different. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Graves’ disease; Hashimoto’s thyroiditis; genetic risk; heterogeneity; large Chinese cohort

Mesh:

Substances:

Year:  2020        PMID: 32246145     DOI: 10.1210/clinem/dgaa170

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Genetics and epigenetics of autoimmune thyroid diseases: Translational implications.

Authors:  Hanna J Lee; Mihaela Stefan-Lifshitz; Cheuk Wun Li; Yaron Tomer
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2022-04-11       Impact factor: 5.667

Review 2.  The Lysophosphatidylserines-An Emerging Class of Signalling Lysophospholipids.

Authors:  Karthik Shanbhag; Amol Mhetre; Neha Khandelwal; Siddhesh S Kamat
Journal:  J Membr Biol       Date:  2020-08-07       Impact factor: 1.843

3.  The effect of radioiodine treatment on the characteristics of TRAb in Graves' disease.

Authors:  Ya Fang; Wen-Hua Du; Cao-Xu Zhang; Shuang-Xia Zhao; Huai-Dong Song; Guan-Qi Gao; Mei Dong
Journal:  BMC Endocr Disord       Date:  2021-11-30       Impact factor: 2.763

4.  Identification of New Rare Variants Associated With Familial Autoimmune Thyroid Diseases by Deep Sequencing of Linked Loci.

Authors:  Cheuk Wun Li; Ravi Sachidanandam; Anitha Jayaprakash; Zhengzi Yi; Weijia Zhang; Mihaela Stefan-Lifshitz; Erlinda Concepcion; Yaron Tomer
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 6.134

5.  Bioinformatics analysis identified shared differentially expressed genes as potential biomarkers for Hashimoto's thyroiditis-related papillary thyroid cancer.

Authors:  Chang Liu; Yu Pan; Qinyu Li; Yifan Zhang
Journal:  Int J Med Sci       Date:  2021-08-13       Impact factor: 3.738

6.  Precision Medicine in Graves' Disease: CD40 Gene Variants Predict Clinical Response to an Anti-CD40 Monoclonal Antibody.

Authors:  Larissa C Faustino; George J Kahaly; Lara Frommer; Erlinda Concepcion; Mihaela Stefan-Lifshitz; Yaron Tomer
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-04       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.